- Start date
- 11 Jul 2024
- End date
- 12 Jul 2024
- Location
- Virtual Meeting
How to access
The ESMO Virtual Plenaries are available to all healthcare professionals working in oncology.
No registration is required to participate. However, you will need to log in with your ESMO membership or free ESMO Account to watch the presentation(s).
Access to the ESMO Virtual Plenary will be open 15 min before each session starts.
Don't have an ESMO account?
Please set up your ESMO Account now to access the ESMO Virtual Plenary.
Programme
18:30-19:30 CEST
Welcome and introduction, Scientific background and context
Amanda Psyrri, Attikon University Hospital, Athens, Greece
Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from cohort B (CPS less-than 1) of the TACTI-003 study
Robert Metcalf, The Christie NHS Foundation Trust, Manchester, UK
Critical analysis and perspectives
Marc Oliva, Institut Català d’Oncologia (ICO) L’Hospitalet, Barcelona, Spain
AACR Expert Commentary
Jong Chul Park, MGH – Massachusetts General Hospital, Boston, MA, USA
Discussion and Q&A (i)
Faculty and online audience
13:00-14:10 CEST
Virtual Plenary Expert Insights: Webcast of 11 July presentations, Discussion and Q&A (ii)
Faculty and online audience
Chair: Makoto Tahara, National Cancer Center Hospital East, Kashiwa, Japan
Robert Metcalf, The Christie NHS Foundation Trust, Manchester, UK
Marc Oliva, Institut Català d’Oncologia (ICO) L’Hospitalet, Barcelona, Spain
Jyoti Bajpai, Apollo Hospital, Navi Mumbai, India
Chia-Chi Lin, National Taiwan University Hospital, Taipei, Taiwan
